PERU NOW, the new international campaign for tourism recovery
9.3.2023 16:43:00 EET | Business Wire | Press release
The campaign "PERU NOW" was launched with great expectations and a live presentation from Machupicchu. Peru returns to the forefront of the world as a diverse, safe and competitive destination.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230307005935/en/
The campaign "Peru Now" targets different countries and showcases glimpses of the beautiful Peruvian destinations. (Photo: PROMPERÚ)
The international strategy implemented by the Commission for the Promotion of Peruvian Exports and Tourism (PROMPERÚ) was presented by Peru's Minister of Foreign Trade and Tourism, Luis Fernando Helguero, and the Executive President of PROMPERÚ, Walter Vizarreta, at ITB Berlin 2023.
This advertising campaign shows everyday moments and views of beautiful landscapes of Peru, including Machupicchu, Huacachina, Gocta, Lake 69, northern beaches, among others. The strategy will reinforce the positive image of Peru and, above all, will inspire tourists to discover the country through its diversity of experiences, culture, landscapes and sensations within an extensive coastline, spectacular Andean landscapes and an exuberant Amazon rainforest.
The articles and digital pieces that will be broadcasted internationally will be spread through important specialized media namely National Geographic, The New York Times, CNN, HBO and the Forbes Group, in addition to different social media platforms, highlighting the exceptional cultural legacy, nature, gastronomy and hotel infrastructure of Peru.
PERU NOW represents an investment of approximately 2 million euros and will be online until April 10, mainly in the cities of Los Angeles, New York, Mexico City, Santiago, Arica, Iquique, Antofagasta, Quito, Cuenca, Loja, Machala, Guayaquil, Bogota, Medellin, Madrid and Barcelona, among others.
The target audience are young and adult travelers comprised of Millennials and Generation X (ages 25 to 54). The approximate campaign audience is 38.9 million people.
Tourism recovery
Tourism is a productive activity that has a great impact on the country's economy and in January of this year, 25 thousand foreign tourists traveled to Peru, and campaigns like PERU NOW, aim to recover the pre-pandemic numbers of visitors in the long term.
The goal of the campaign is to build confidence in future travelers, forging a bond that will inspire them to consider our country in the bucket list of destinations for their next trips, and also to maintain the awareness of our brand.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005935/en/
Contact information
Rocío Pachari
51997707434
rpachari@promperuext.pe
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom